MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Lantheus Holdings DSO Ratio 2011-2026 | LNTH
Annual DSO Ratio Lantheus Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 72 | 70.1 | 59.1 | 61.5 | 52.4 | 45.7 | 46.5 | 44.3 | 44.5 | 46.4 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 72 | 44.3 | 54.3 |
Quarterly DSO Ratio Lantheus Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 81.7 | 82.7 | 82 | - | 84.5 | 82.2 | 76.7 | - | 73.5 | 70.7 | 69.1 | - | 37.6 | 35.1 | 57.1 | - | 53.2 | 51.4 | 55.7 | - | 55.6 | 74.7 | 49.1 | 44.5 | 46.3 | 46.4 | 46 | 46.3 | 44.9 | 46.7 | 46.4 | 45.2 | 46 | 41.4 | 43.2 | 45.2 | 46 | 43.1 | 44.2 | 47.8 | 45.9 | 46.4 | 48.1 | 49.2 | 50.1 | 25.1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 84.5 | 25.1 | 53.8 |
DSO Ratio of other stocks in the Diagnostics research industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
275 | $ 3.04 | -1.94 % | $ 98.7 K |  USA |
 |
Centogene N.V.
CNTG
|
145 | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
50.7 | - | -6.19 % | $ 10.5 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
31.7 | $ 34.06 | 0.86 % | $ 367 M |  China |
 |
Biocept
BIOC
|
112 | - | -13.05 % | $ 7.29 M | USA |
 |
Accelerate Diagnostics
AXDX
|
291 | - | -61.36 % | $ 2.46 M | USA |
 |
BioNano Genomics
BNGO
|
83.4 | $ 1.3 | - | $ 1.65 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
90.8 | - | - | $ 562 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
66.3 | - | 0.22 % | $ 16.8 M | USA |
 |
Danaher Corporation
DHR
|
57 | $ 218.89 | - | $ 160 B | USA |
 |
Co-Diagnostics
CODX
|
101 | - | - | $ 79.8 M | USA |
 |
Castle Biosciences
CSTL
|
49.2 | $ 39.39 | - | $ 1.09 B | USA |
 |
Exact Sciences Corporation
EXAS
|
29.9 | $ 102.34 | - | $ 19 B | USA |
 |
DermTech
DMTK
|
80.6 | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
112 | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
67.2 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
11.7 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
122 | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
98.1 | - | - | $ 10.7 B | USA |
 |
DexCom
DXCM
|
85 | $ 73.04 | -1.3 % | $ 28.2 B | USA |
 |
Guardant Health
GH
|
49.2 | $ 114.04 | - | $ 14 B | USA |
 |
CareDx, Inc
CDNA
|
76.4 | $ 20.55 | -1.2 % | $ 1.1 B | USA |
 |
DarioHealth Corp.
DRIO
|
85.8 | $ 10.02 | - | $ 284 M |  Israel |
 |
Enzo Biochem
ENZ
|
50.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
77.4 | $ 26.2 | - | $ 792 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
101 | - | -20.0 % | $ 1.06 M | USA |
 |
Heska Corporation
HSKA
|
40.8 | - | - | $ 1.31 B | USA |
 |
IDEXX Laboratories
IDXX
|
43.6 | $ 670.46 | - | $ 55.3 B | USA |
 |
Illumina
ILMN
|
61.3 | $ 144.81 | -3.26 % | $ 23 B | USA |
 |
QIAGEN N.V.
QGEN
|
30.8 | - | - | $ 10.6 B |  Niderland |
 |
IQVIA Holdings
IQV
|
78 | $ 230.15 | - | $ 41.7 B | USA |
 |
Medpace Holdings
MEDP
|
51.5 | $ 582.48 | - | $ 18 B | USA |
 |
Charles River Laboratories International
CRL
|
67.7 | $ 210.48 | - | $ 10.8 B | USA |
 |
NeoGenomics
NEO
|
77.8 | $ 12.06 | - | $ 1.53 B | USA |
 |
National Research Corporation
NRC
|
33 | $ 20.34 | - | $ 499 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
46.5 | $ 187.03 | - | $ 20.8 B | USA |
|
Biodesix
BDSX
|
41.7 | $ 10.17 | - | $ 1.32 B | USA |
 |
Precipio
PRPO
|
28.1 | $ 24.54 | - | $ 31.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
54.1 | $ 271.52 | - | $ 22.8 B | USA |
 |
ICON Public Limited Company
ICLR
|
68.5 | $ 180.25 | - | $ 14.9 B |  Irlanda |
 |
Agilent Technologies
A
|
63.8 | $ 133.85 | - | $ 40.7 B | USA |
 |
Biomerica
BMRA
|
57.7 | $ 2.38 | - | $ 5.47 M | USA |
 |
OpGen
OPGN
|
4.66 | - | -16.95 % | $ 1.54 M | USA |
 |
Bioventus
BVS
|
92.3 | $ 7.93 | - | $ 497 M | USA |